Use of antimigraine treatments by general practitioners

Headache

Volumn 51, Issue 7, 2011, Pages 1122-1131

  Ducros, Anne ^a   Romatet, Sophie ^b   Saint Marc, Thierry ^c   Allaf, Bashar ^d  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Hôpital de Poissy St Germain   (France)

^c General Practices ^*  (France)

^d Almirall SAS   (France)

Author keywords

migraine; primary care; prophylaxis; treatment; triptan

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ERGOT ALKALOID; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROPRANOLOL; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; GENERAL PRACTITIONER; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT;

ACTIVITIES OF DAILY LIVING; ADULT; ANALGESICS; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; GENERAL PRACTITIONERS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT COMPLIANCE; PRESCRIPTION DRUGS; QUESTIONNAIRES; SELF REPORT;

EID: 79960595376     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01939.x     Document Type: Article

References (28)

1. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF,. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003; 23: 441-450. (Pubitemid 36776060)
2. Duru G, Auray JP, Gaudin AF, et al,. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache. 2004; 44: 571-580. (Pubitemid 38780348)
3. Pradalier A, Auray JP, El Hasnaoui A, et al,. Economic impact of migraine and other episodic headaches in France: Data from the GRIM2000 study. Pharmacoeconomics. 2004; 22: 985-999. (Pubitemid 39472624)
4. Edmeads J, Mackell JA,. The economic impact of migraine: An analysis of direct and indirect costs. Headache. 2002; 42: 501-509. (Pubitemid 37011822)
5. Michel P, Dartigues JF, Duru G, Moreau J, Salamon R, Henry P,. Incremental absenteeism due to headaches in migraine: Results from the Mig-Access French national cohort. Cephalalgia. 1999; 19: 503-510. (Pubitemid 29309041)
6. Stang P, Cady R, Batenhorst A, Hoffman L,. Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics. 2001; 19: 231-244. (Pubitemid 32230938)
7. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657. (Pubitemid 32777747)
8. Lipton RB, Stewart WF, Celentano DD, Reed ML,. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992; 152: 1273-1278.
9. Lantéri-Minet M, Massiou H, Nachit-Ouinekh F, et al,. The GRIM2005 study of migraine consultation in France I. Determinants of consultation for migraine headache in France. Cephalalgia. 2007; 27: 1386-1397. (Pubitemid 350150797)
10. Lipton RB, Stewart WF, Simon D,. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998; 38: 87-96. (Pubitemid 28155226)
11. MacGregor EA, Brandes J, Eikermann A,. Migraine prevalence and treatment patterns: The global Migraine and Zolmitriptan Evaluation survey. Headache. 2003; 43: 19-26. (Pubitemid 36150986)
12. Diener HC, Limmroth V,. Medication-overuse headache: A worldwide problem. Lancet Neurol. 2004; 3: 475-483. (Pubitemid 38903098)
13. Lucas C, Lanteri-Minet M, Massiou H, et al,. The GRIM2005 study of migraine consultation in France II. Psychological factors associated with treatment response to acute headache therapy and satisfaction in migraine. Cephalalgia. 2007; 27: 1398-1407. (Pubitemid 350150803)
14. Lucas C, Geraud G, Valade D, Chautard MH, Lanteri-Minet M,. Recognition and therapeutic management of migraine in 2004, in France: Results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006; 46: 715-725.
15. Geraud G, Lanteri-Minet M, Lucas C, Valade D,. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004; 26: 1305-1318. (Pubitemid 39445352)
16. Brockmann N, Evers S,. Migraine in headache specialists and neurologists. Schmerz. 2008; 22 (Suppl. 1): 47-50.
17. Weber M, Daures JP, Fabre N, et al,. Influence of general practitioners' personal knowledge on migraine in medical attitudes towards their patients suffering from migraine. Rev Neurol (Paris). 2002; 158: 439-445. (Pubitemid 34475149)
18. Lantéri-Minet M, Massiou H, Romatet S, Barba A, Lucas C, Allaf B,. An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study). Headache. 2011; 51: 590-601.
19. Haute Autorité de Santé. Clinical practice guidelines. Chronic daily headache (CDH) - Diagnosis, medication overuse, and management. http://www.has-sante.fr/portail/upload/docs/application/pdf/CCQ-guidelines.pdf. Paris 2004.
20. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C,. Migraine and probable migraine-results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia. 2005; 25: 1146-1158. (Pubitemid 41774861)
21. Donnet A, Becker H, Allaf B, Lantéri-Minet M,. Migraine and migraines of specialists: Perceptions and management. Headache. 2010; 50: 1115-1125.
22. Donnet A, Lanteri-Minet M, Aucoin F, Allaf B,. Use and overuse of antimigraine drugs by pharmacy personnel in France: COTA survey. Headache. 2009; 49: 1014-1021.
23. Dib M,. Optimizing prophylactic treatment of migraine: Subtypes and patient matching. Ther Clin Risk Manag. 2008; 4: 1061-1078.
24. Massiou H,. [Prophylactic treatments of migraine]. Rev Neurol (Paris). 2000; 156 (Suppl. 4): 4S79-4S86. (Pubitemid 32107181)
25. Direction de la recherche dé, de l'évaluation et des statistiques DREES. Document de travail. Les médecins Estimations au 1er janvier 2007. 2007;n°115-août-septembre 2007.
26. Brandes JL,. Global trends in migraine care: Results from the MAZE survey. CNS Drugs. 2002; 16 (Suppl. 1): 13-18.
27. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M,. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia. 2005; 25: 267-279. (Pubitemid 40445811)
28. MacGregor EA, Brandes J, Eikermann A, Giammarco R,. Impact of migraine on patients and their families: The Migraine And Zolmitriptan Evaluation (MAZE) survey-Phase III. Curr Med Res Opin. 2004; 20: 1143-1150. (Pubitemid 38954477)